Axa’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Axa’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,400	Closed	-$754K	–	1312
2020 Q1	$754K	Buy	+15,400	New	+$785K	﹤0.01%	903

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Axa's EIDX Position: Q2 2020 in Review

Axa sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q2 2020, closing a stake of 15,400 shares — an estimated $754K sold.

Axa first reported a position in EIDX in Q1 2020 and held it in 1 quarter. The position peaked at $754K in Q1 2020. 92 funds tracked by Wall St. Rank hold EIDX as of Q2 2020.

Axa reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Axa sold 15,400 Eidos Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $754K.
Axa first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
Axa's Eidos Therapeutics, Inc. Common Stock position peaked at $754K in Q1 2020.
92 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Axa's 13F filing for Q2 2020, filed 14 Aug 2020.